Improving treatment for a type of blood cancer called AML with FLT3 mutations
Improving targeted therapy in FLT3-mutated AML
This study is looking at ways to make treatments for acute myeloid leukemia (AML) work better for patients with FLT3 mutations by figuring out why some therapies stop being effective, so we can find new and improved options for you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10862857 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain therapies targeting FLT3 mutations in acute myeloid leukemia (AML) can be improved. The project involves studying the mechanisms that lead to resistance against these therapies, which are designed to eliminate leukemia cells. By investigating the signaling pathways affected by FLT3 inhibitors, the research aims to identify new strategies to enhance the effectiveness of these treatments. Patients may benefit from insights gained that could lead to more effective therapies for AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have FLT3 mutations.
Not a fit: Patients with AML who do not have FLT3 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with FLT3-mutated AML, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting FLT3 mutations in AML, but this specific approach to understanding resistance mechanisms is relatively novel.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Sung, Pamela Jeannette — Roswell Park Cancer Institute Corp
- Study coordinator: Sung, Pamela Jeannette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.